Note: The excerpt below was written earlier this morning by Hedgeye CEO Keith McCullough. Stay tuned for further updates from our Healthcare sector head Tom Tobin.
Looking for names that my Research Team likes that are:
1. Bullish intermediate-term TREND duration
2. Immediate-term TRADE oversold within their bullish TREND
Hologic is a name Tom Tobin has liked for a while, but he's also becoming the axe in the name with regards to monitoring the company's key revenue factors using his proprietary process.
In what Tom calls his 3D TOMO Tracker Update (Institutional Research product) of US facilities currently offering 3D Tomosynthesis, month-to-date December placements signaled a break-out quarter after a sharp acceleration in October and slight correction to a still very high rate in November.
We believe we are seeing a sustained acceleration in placements that will likely drive upside to Breast Health throughout FY2015.